Synthetic amphipathic peptides resembling apolipoproteins stimulate the release of human placental lactogen by Jorgensen, E et al.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 264, No. 16, Issue of June 5, pp. 9215-9219,1989 
0 1989 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U. S. A. 
Synthetic Amphipathic Peptides  Resembling  Apolipoproteins 
Stimulate  the  Release of Human Placental  Lactogen* 
(Received for publication, October 20, 1988) 
E. Verena JorgensenlP, G. M. Anantharamaiahn, Jere P. Segrestll, 
John T. Gwynne 11 , and Stuart HandwergerS** 
From  the  Departments of $Pediatrics  and **Physiology, Duke University  Medical  Center, Durham,  North Carolina 27710, 
the YDepartments of Pathology, Biochemistry, and Medicine and  the Atherosclerosis Research Unit, University of Alabama, 
Birmingham, Alabama 35294, and  the 11 Department of Medicine, University of North Carolina, Chapel Hill, 
North Carolina 27514 
Previous studies from our laboratory demonstrated 
native high density lipoproteins and apolipoproteins 
AI,  AII, and CI, stimulate the release of  human placen- 
tal lactogen (hPL) from trophoblast cells in culture. To 
examine the mechanisms by which these apolipopro- 
teins stimulate hPL release, we have studied hPL se- 
cretion  in response to several synthetic peptide analogs 
of the amphipathic helical structure of the apolipopro- 
teins. The magnitude of the stimulation of hPL release 
in response to the analog peptides correlated with the 
ability to displace apolipoproteins from high density 
lipoprotein and with other measures of phospholipid 
binding affinity such as the increase in a-helicity and 
the size of complexes formed between the peptide and 
phospholipid. The correlation of stimulatory ability 
and lipid affinity  suggests that the action of the apoli- 
poproteins on hPL release may be mediated through 
an interaction with plasma membrane phospholipids. 
Human placental lactogen (hPL)’ is a 22.5-kDa protein 
hormone synthesized and secreted by the placental syncytio- 
trophoblast which has  striking homologies in chemical, bio- 
logical, and immunological properties to growth hormone and 
prolactin (1, 2). The hormone is first detected in maternal 
blood at about 6 weeks of gestation and increases in concen- 
tration at a relatively linear rate  until 34 weeks, reaching a 
maximal concentration of 6000-8000 ng/ml (3). The factors 
involved in the regulation of the synthesis  and release of hPL, 
however, are poorly understood. We have recently demon- 
strated that high density lipoprotein (HDL) at physiologic 
concentrations  stimulates the release of the protein hormone 
hPL from an enriched fraction of cultured trophoblast cells 
and  that  the activity is  due to apolipoproteins AI, AII, and CI 
and  not  the lipid constituents on HDL (4). Since trophoblast 
membranes have receptors for HDL ( 5 )  and plasma levels of 
HDL  and hPL increase concomitantly during pregnancy (6), 
these findings suggest a physiologic role for HDL in hPL 
secretion. 
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Apolipoproteins are noncovalently bound to  the outer layer 
of HDL and  are integral to the organization and metabolism 
of the lipoproteins (7). The amphipathic helix is generally 
accepted to be the structural form of the lipid-associating 
domains of the exchangeable apolipoprotein classes A,  C, and 
E (8). The amphipathic helix  model defines a general a-helical 
domain containing opposing polar and nonpolar faces and a 
specific distribution of charged residues. Positively charged 
residues are  distributed at  the interface between the polar and 
nonpolar faces, and negatively charged residues occur along 
the  center of the polar face. The presence of the amphipathic 
lysine and arginine residues at the polar/nonpolar face inter- 
faces increases the  amphipathicity of the  amphipathic helical 
domains of the apolipoproteins. Interfacial basic residues 
distinguish the  amphipathic helixes in apolipoproteins from 
amphipathic helixes in other classes of proteins. 
Apolipoprotein A1 (apoAl)  contains eight tandem 22-mer 
repeats at its carboxyl-terminal end, each of which has the 
properties of an amphipathic helical domain (9). To examine 
whether this  characteristic  structure of the apolipoproteins is 
also important in the stimulation of hPL release, we have 
examined the effects on hPL release of several synthetic 
peptides that were designed to mimic the apolipoproteins in 
their  structure  and properties. 
MATERIALS  AND  METHODS 
Peptide  Synthesis  and Apolipoprotein Preparation-Peptides were 
synthesized by the  solid-phase  method of peptide  synthesis  as previ- 
ously described (10, 11). HDL was prepared by sequential  flotation 
ultracentrifugation of normolipemic plasma  (density 1.125-1.215 g/ 
ml) as described by Shumaker and Puppione (12), then dialyzed 
against  three  changes of 0.15 M NaC1, 0.3 mM EDTA,  pH 7.4, and 
stored at  4 “C. Apolipoproteins A1 and AI1 were prepared by DEAE 
molecular sieve chromatography  (13) of delipidated HDL  and  simi- 
larly dialyzed. Analysis by overload  (100 Fg) sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis indicated proteins were >98% 
purified. 
Trophoblast Culture  and  hPL Release Studies-Enriched fractions 
of hPL producing trophoblast cells were prepared from term  placentas 
using  collagenase and  hyaluronidase digestion and isopycnic centrif- 
ugation  on 40% Percoll gradients  as previously described (14). Dis- 
persed  cells were cultured  in 24-well plastic  plates  coated  with  Vitro- 
gen-100 a t  0.5 million cells in 1 ml of RPMI 1640 medium with L- 
glutamine  and sodium bicarbonate  (GIBCO)  and 5% fetal calf serum. 
After 24 h,  the cells were washed with  RPMI 1640 without  fetal calf 
serum  and  the  peptides added to  triplicate wells. Aliquots of media 
were removed at   the appropriate  times,  and media was assayed for 
hPL by specific homologous  radioimmunoassay (15). Results are 
expressed as nanograms of bPL released/milliliter. 
Perifusion Studies-Dispersed trophoblast cells were placed into 
an Endotronics Micro Module perifusion system, 10 million cells/ 
chamber, and perifused with RPMI 1640 a t  6 ml/h as previously 
described (16). After a 2-h equilibration period, the  chambers were 
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perifused with media  only or media containing HDL, apoAII, or 18A- 
Pro-18A for  15 min, then returned to control media. One- or 5-min 
fractions were collected and assayed for hPL  as above. 
Synthetic Peptides-Multilamellar vesicles of DMPC were pre- 
pared by vortexing DMPC in phosphate buffer (10 mM in 150 mM 
NaCl, pH 7.0). Peptides in the same buffer were mixed with the 
multilamellar vesicle suspension at a 1:5 weight ratio. Complexes 
were measured by electron microscopy as previously described (11, 
17). Percent helicity of peptides was measured by circular dichroism 
in phosphate buffer (10 mM in 150 mM NaCl, pH 8.0) directly or 
after forming complexes with DMPC (1:2.5 peptide to DMPC weight 
ratio). The data on complex size and percent helicity has been 
published previously (11, 17). Displacement of native apolipoproteins 
from HDL was determined by incubation of 1:l weight ratio of peptide 
and '"I-HDL overnight with quantification of free apolipoproteins 
by counting of electrophoretically separated proteins (10). 
Statistical Analysis-Each experiment was performed in  triplicate 
and statistical analyses were performed using analysis of variance. 
Contrasts were performed using Scheffe's test. 
RESULTS 
The synthetic peptides used in this study were designed to 
examine how the amphipathic a-helical regions of apolipopro- 
teins contribute to  their lipid binding and biological function 
(11, 12). They have been well characterized in earlier works 
and have been shown to form complexes with phospholipids 
(17), exchange with native apolipoproteins on HDL (18), and 
serve as cofactors in the lecithin/cholesterol acyltransferase- 
mediated catalysis of cholesterol ester formation (19). The 
model peptide, peptide HA, is 18-amino acid residues long 
and forms an a-helix with a  polar and a nonpolar face and a 
specific distribution of charged residues. It has positively 
charged amino acid residues at  the interface of the polar and 
nonpolar faces and negatively charges residues along the 
center of the polar face. The amino acid sequences of the 
synthetic peptides examined and a space filling model of 
peptide 18A are shown in Fig. 1. 
When added to cultured  trophoblast cells, the amphipathic 
peptides which mimic the properties of apoAl stimulated  a 
significant, dose-dependent increase in hPL release (Fig. 2). 
The model peptide, peptide MA, stimulated an 8.5-fold in- 
crease in hPL release over control cells. Peptide 18A-Pro-18A 
stimulated more release than  the single helical peptide MA, 
with a maximal 18-fold increase in hPL release. This peptide 
Polar  Face  Non-Polar  Face 
FIG. 1. Space filling model of 18A amphipathic peptide. 
Stippled areas indicate positively charged amino acid residues, and 
striped arem indicate negatively charged residues. 18A Asp-Trp-Leu- 
Lys-Ala-Phe-Tyr-Asp-Lys-Val-Ala-Glu-Lys-Leu-Lys-Glu-Ala-Phe. 
Model amphipathic helix representing the charged residue positions 
analogous to apolipoproteins. Reverse-MA: Lys-Trp-Leu-Asp-Ala- 
Phe-Tyr-Lys-Asp-Val-Ala-Lys-Glu-Leu-Glu-Lys-Ala-Phe. Charged 
residue positions in 18A reversed. (Glu'~sLeu11~")18A: Asp and Ala 
were substituted with Glu and Leu at positions indicated to increase 
the lipid affinity of 18A. 18A-Pro-18A: repeating units of  18A joined 
by Pro. This increases the lipid affinity by cooperativity between the 
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FIG. 2. Stimulation of hPL release by apolipoprotein ana- 
logs and apoAl. Enriched fractions of hPL producing trophoblast 
cells  were prepared from term  placentas as described under "Materials 
and Methods," and cultured at 0.5 million cells in 1 ml  of RPMI 1640 
medium with 1% fetal calf serum. After 24 h, the cells were washed 
with RPMI 1640 without fetal calf serum and  the peptides added to 
triplicate wells. Aliquots of media were  removed at 1 h, and  the media 
was assayed for hPL,  results  are expressed as ng of hPL released/ml 
in 1 h. Symbols indicate mean * S.E.,  where error  bars are not shown 
the S.E.  was less that  the height of the symbol. Control (O), apoAl 
(O), 18A-Pro-18A (A), 18A (A), (Glu'~8Leu''~'8)18A (B), reverse-18A 
(0). Statistical differences from control are indicated by * p < 0.05, 
** p < 0.001. 
has two model helixes joined by a proline, giving it the 
potential for cooperativity between helixes as  the two helical 
segments can pivot around proline (an amino acid which does 
not  permit helix formation). Increasing the hydrophobicity of 
18A  by substitution of glutamic acid residues for aspartic acid 
and leucine for alanine, compound (Gl~ '~~Leu"~'~) l8A,  
changed the shape of the dose response curve and increased 
the  amount of hPL released at  higher concentrations (10.5- 
fold increase at 150 pg/ml). Reverse-MA, which has the 
position of positive and negative charges reversed, had no 
effect on hPL release. ApoAl stimulated  a 3.1-fold increase 
in hPL release. Intact HDL stimulated 2.2-fold increase at  
concentrations of 1.0-1.5 mg protein/ml (data not shown). 
The dose response curves for apoAl  and peptides 18A and 
18A-Pro-18A reached different maximum effects, but all three 
had the same half-maximal effective concentration of =25 Kg/ 
ml. The dose response curve for peptide (Gl~'~~Leu"~'~)18A 
did not reach a maximum effect at  the doses tested. 
Previous studies have shown that  the affinity of a  peptide 
for lipids can be represented by the diameter of the  protein- 
lipid discoidal structures formed with phospholipids such as 
DMPC, with smaller complexes indicating greater affinity 
(10). As shown in  Table I, 18A-Pro-18A and  the more hydro- 
phobic (Gl~~~~Leu". '~)18A both form small complexes, 
whereas changing the distribution of the charged residues as 
in reverse-l8A causes the formation of large complexes which 
are unstable.  Peptide 18A. DMPC complexes are intermediate 
in size. The lipid affinity of these  peptides  correlates with the 
magnitude of maximal hPL release, with 18A-Pro-18A and 
(Gl~',~Leu",'~)18A stimulating the most release, reverse-18A 
being inactive, and 18A intermediate  in  stimulatory activity. 
Another characteristic of the apolipoproteins and  other lipid- 
associating proteins is an increase in helicity upon interaction 
with phospholipids, as measured by circular dichroism (20). 
Peptide reverse-18A exhibits low percent  a-helicity  both  in 
buffer and in the presence of DMPC, whereas peptide 18A 
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TABLE I 
Comparison of hPL release with lipid affinity of amphipathic  peptide analogs 
Displacement 
Analog peptide peptide: DMPC stimulation of apolipoproteins 
from HDL' 
Diameter of 
complex (A)" Buffer DMPC 
% helicityb % Maximal % 
hPL release 
18A-Pro-18A 148 k 19 49  53 21.0 1840 
[Gl~'~~Leu''~'~]  18A 123 -t 46 22 44 12.7 1050 
1 RA 206 k 30 15  30 11.3 850 
Reverse-lBA 237 k 26  11  12 2.0 128 
Diameter of peptide-DMPC complex determined by electron microscopy after incubation at 1:5 weight ratio 
mixture. 
ellipticity at 222 nm. 
overnight with quantification of  free apolipoproteins by counting of electrophoretically separated proteins. 
peptide for 1 h and results expressed as percent increased release over control. 
* Measured  by  circular dichroism where percent helix = ( 0 2 2 2  + 3000/3900) X 100  where 0 2 2 2  is the mean  residue 
Displacement of apolipoproteins determined by incubation of 1:l weight ratio of peptide and iodinated HDL 
HPL stimulation was performed as described under "Materials and Methods." The cells were exposed to 
500r 
- r; 400 
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FIG. 3. The release of hPL by perifused trophoblasts ex- 
posed to equimolar amounts of HDL (O), apoAII (0), and 
peptide 1SA-Pro-1SA (+). Dispersed trophoblast cells were placed 
into a perifusion system, 10 million cells/chamber, and perifused with 
RPMI 1640 at 6 ml/h. After a 2-h equilibration period, the chambers 
were perifused with media only or media containing HDL (1 mg/ml), 
apoAII (200 pg/ml) or 18A-Pro-18A (50 pg/ml) for 15 min, then 
returned to control media. One- or 5-min fractions were collected and 
assayed for hPL. 
displays a doubling of percent a-helicity with phospholipids 
and (Gl~'~~Leu"~'~)18A increases 2.5-fold. Peptide 18A-Pro- 
18A is already 50% helical in buffer and shows little  further 
increase with DMPC; this may be due to  the two or more 
nonpolar faces self-associating in aqueous solution to mini- 
mize aqueous contact and thereby stabilizing the a-helical 
structure (17). 
The ability of the peptide analogs to associate with lipids 
can  perhaps best be summarized by their capacity to displace 
native apolipoproteins from the surface of lipoprotein parti- 
cles. Table  I shows that  the analogs displace iodinated apoli- 
poproteins from HDL with rank order ability 18A-Pro-18A > 
(Glu'~*Le~"~'~)l8A > 18A > reverse-18A. Maximum stimula- 
tion of hPL release by peptide analogs shows the same rank 
order. These findings indicate that  the same compounds that 
are the most potent  stimulators of hPL release also bind most 
avidly with phospholipids. The characteristics of high a- 
helicity, nonpolar face hydrophobicity and  a specific charge 
distribution appear important to both hPL release and phos- 
pholipid association. 
As shown in Fig. 3, the time course of the stimulation of 
hPL release by 18A-Pro-18A was identical to  that of HDL 
and apolipoprotein AII. Trophoblast cells perifused with 
equimolar' amounts of 18A-Pro-l8A, apoAII, or native HDL 
Molecular weights used are: 18A-Pro-18A 400; apoA1 17,400; and 
HDL 74,000 (assuming an average of two apoAI and one apoAII/ 
HDL moiety) (7). 
all released hPL within 5 min of exposure, and  the  pattern of 
response of the  three compounds was essentially identical. 
The release of hPL  in response to  the amphipathic peptides 
is not due to a "non-specific" detergent effect of the peptides 
since the increase in  hPL release was not accompanied by the 
leakage of the cytosolic enzymes lactic dehydrogenase and 
alkaline phosphatase  and nonhelical detergents have no effect 
on hPL release (data  not shown). For example, deoxycholate 
in a molar concentration 10-fold greater than  that of 18A- 
Pro-18A caused no increase in hPL secretion. Triton X-100 
in 10-fold excess did cause an increase in  hPL release but  the 
increase was accompanied by the leakage of cystolic enzymes 
into the medium. Peptide 18A-Pro-18A stimulated  a specific 
release of hPL, i.e. without release of intracellular enzymes. 
DISCUSSION 
These  studies indicate that synthetic peptides which  mimic 
the structure of the lipid-associating domains of the exchange- 
able apolipoproteins cause a specific, rapid, dose-dependent 
release of hPL from trophoblast cells with an identical time 
course as  the apolipoproteins. These findings suggest that  the 
secondary structure of an amphipathic a-helix is the func- 
tional unit in the HDL-stimulated release of hPL from troph- 
oblast cells. Variations of the model peptide indicate that 
hydrophobicity, a-helicity,  and  a specific charge distribution 
all contribute to both the  hPL stimulatory activity and  to  the 
ability to associate with phospholipids. The parallel nature of 
these requirements indicates that lipid binding may be a 
necessary function of an active analog of the amphipathic 
helix and suggests that these peptides may  be working through 
interaction with cell phospholipids, most likely those of the 
plasma membrane. 
The finding that the ability to stimulate hPL release is 
governed by secondary structure  rather than a specific amino 
acid sequence and that several variations of the model peptide 
are very  effective stimulators argues against a "lock and key" 
type of protein ligand-receptor interaction  as the first  step in 
stimulation. The correlation of hPL stimulation and phos- 
pholipid affinity suggests that a protein-lipid interaction may 
instead be important. Indeed, the amphipathic a-helix por- 
tions of the apolipoproteins are believed to be the lipid- 
binding domains (8). The ability of the analog peptides to 
stimulate greater amounts of hP1 release than apoAl may 
indicate that these membrane-interactive portions  are more 
accessible in  the smaller compounds. Since the nonpolar face 
of the apolipoproteins is believed to be associated with lipo- 
protein phospholipids in the  intact HDL moiety, part or  all 
of the apolipoprotein molecule would theoretically need to 
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reassociate with the cell membrane phospholipids. The lack 
of previous phospholipid binding may explain why the delip- 
idated apolipoprotein is effective at a 10-fold lower concen- 
tration  than  intact HDL. The dose response curves for apoAl 
and peptides 18A and 18A-Pro-18A reached different maxi- 
mum effects, suggesting that  there were a limited number of 
sites on the membrane at which these compounds could act, 
and  that  the peptides with higher lipid binding affinity had 
more sites available for interaction. The similar half-maximal 
effective  doses suggests that they  are all interacting with the 
membrane through the same mechanism. Peptide 
(Gl~ '~~Leu'~~'~)18A appears to have a biphasic dose response 
curve, with the increase in hydrophobicity allowing greater 
membrane interaction at higher concentrations. 
Association of the analogs with the phospholipids of the 
cell membrane may lead to focal changes in the properties of 
the membrane, such as membrane fluidity and/or permeabil- 
ity. Alterations in membrane permeability causing, for ex- 
ample, influx of calcium ions could stimulate second messen- 
ger production, such as  an increase in CAMP levels. Alterna- 
tively, a change in membrane fluidity or lipid bilayer 
organization could activate  a membrane-bound phospholipase 
activity with subsequent release of phosphoinisitols, diacyl- 
glycerol, or  other  intracellular regulators. These mechanisms 
would  be analogous to  the action of polycations, such as poly- 
L-lysine,  which are believed to exert  their biological actions 
through electrostatic  interactions of their positively charged 
amino acids with the negatively charged surface of cells (21). 
Poly-L-lysine has been found to  alter membrane permeability 
(22) and to stimulate  a calcium-dependent phospholipase (23). 
Changes in membrane permeability could also be affected by 
the creation of ion-conducting pores. Ion channel  proteins  are 
composed of multiple homologous subunits, each of which 
appears to contain numerous membrane-spanning amphi- 
philic a-helixes, and 21-residue synthetic peptides designed 
to form amphiphilic a-helixes which have a high degree of 
hydrophobicity have recently been shown to form ion chan- 
nels (24). 
I t  is also possible that  the apolipoprotein analogs stimulate 
hPL release by binding to a membrane protein that has a 
general affinity for amphipathic helixes. Calmodulin is known 
to bind with high affinity a variety of peptides which share  a 
potential  amphipathic  a-helix  structure, such as melittin (25), 
mastoparan  (26), chicken gizzard  myosin light chain kinase 
fragments (27), @-endorphin, and @-endorphin analogs (28). 
A similar membrane protein binding phenomenon where the 
secondary structure of an amphipathic  a-helix is the deter- 
mining characteristic could mediate the action of the variety 
of apolipoprotein analogs and therefore of the various apoli- 
poproteins. 
There  are marked similarities between the apolipoprotein 
analogs and several peptide hormones. Several authors have 
proposed the existence of a category of protein hormones that, 
despite diverse biological functions and nonhomologous se- 
quences, share a number of structural similarities (29, 30). 
These hormones are single stranded, of intermediate length 
(10-50 amino acid residues), lack a definite tertiary  structure, 
have hydrophobic residues regularly spaced every 3 to 4 resi- 
dues giving the potential for amphipathic helix formation, 
and form stable complexes with phospholipids. Examples of 
this class of peptide hormones include glucagon, calcitonin, 
the fully active parathyroid hormone fragment 1-34, and @- 
endorphin. Synthetic peptide analogs with conservative sub- 
stitutions through the potential  amphipathic helix areas show 
retention of binding and biological activity, indicating that 
the amphipathic  a-helix  rather  than the specific amino acid 
sequence is the critical factor (29). Corticotropin-releasing 
factor is another biologically active peptide which  is  believed 
to fold into two amphipathic  a-helical domains during  inter- 
action with the cell membrane (31). 
Although this class of hormones and  the apolipoproteins 
share an amphipathic helical nature, the hormones mentioned 
have segments which cannot  tolerate  substitutions, usually at 
the amino terminal end. This required region is believed to 
be important in high affinity receptor interaction,  as in amino 
acid residues 1-5 of @-endorphin (30), whereas the amphi- 
pathic helical areas of this family of hormones is postulated 
to interact with plasma membrane phospholipids and  thereby 
to aid in proper positioning of the hormone to  the receptor 
(32). The apolipoprotein analogs, in  contrast,  are fully substi- 
tuted, again suggesting that they may not require interaction 
with a receptor moiety. 
In conclusion, these studies of the apolipoprotein analogs 
indicate that  the amphipathic  a-helix is important  not only 
in apolipoprotein-lipid association but in the interaction of 
apolipoproteins and  intact cells. The analogy with other pep- 
tide hormones illustrates the general biological importance of 
the amphipathic a-helix configuration. The correlation of 
hPL stimulatory ability and phospholipid binding affinity, 
and  the lack of an amino acid-specific region,  suggest that  the 
analog peptides and therefore the apolipoproteins themselves 
may influence hPL release by direct  interaction with plasma 
membrane phospholipids. 
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